“TNFR2 is a tissue Treg-enriched gene predominantly expressed by suppressive Tregs in skin and gut. Our development candidate TRB-061 is designed to selectively agonize TNFR2, ...

Researchers at the Stanford University School of Medicine have identified a group of mutations responsible for many cases of a rare immune cell cancer called cutaneous T-cell lymphoma. Identifying ...

The FDA has cleared BITT’s IND application for a Phase I trial of BITT2101 (anti-TNFR2) in patients with relapsed/refractory Non-Hodgkin’s lymphomas ...

According to Lo, mice that have a genetic deficiency in TNFR2 get much more severe disease, suggesting that TNFR2 does indeed have beneficial effects. "Without TNFR2, IBD is a lot worse," he said.

Targeting the TNFR2 oncogene on tumor cells and tregs of the tumor microenvironment via dominant TNFR2 antagonism.. JCO 35 , 106-106 (2017). DOI: 10.1200/JCO.2017.35.7_suppl.106 ...

Targeting TNFR2 is anticipated to yield effective anti-tumor immunity by stimulating T-cell and NK-cell activation and proliferation in the tumor microenvironment. HFB200301 is a first-in-class ...

- Study explores potential in solid tumors and cutaneous T-cell lymphoma - BI-1808 is one of three BioInvent drug candidates in clinical development LUND, Sweden, April 7, 2021 /PRNewswire ...

Program is the Product of a Research Collaboration between Biolojic Design and Nektar entered in 2021TEL AVIV, Israel and SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- Biolojic Design, a ...

Multinational antibody specialist Hifibio Therapeutics Inc. closed an oversubscribed $75 million series D financing round to move its anti-TNFR2 antibody HFB-200301 and the anti-OX-40 antibody ...

LUND, Sweden, April 7, 2021 /PRNewswire/ -- BioInvent International AB ('BioInvent') (Nasdaq Stockholm: BINV) today announced that the U.S. Food a ...